Little Rock, ARNCT07224009Now EnrollingIRB Ready

Metastatic Prostate Cancer Clinical Trial in Little Rock, AR

Access cutting-edge metastatic prostate cancer treatment through this phase 2 clinical trial at a research site in Little Rock. Study-provided care at no cost to qualified participants.

Sponsored by University of Arkansas

Quick Self-Assessment

See if you qualify for this Little Rock location

Preparing your pre-screening questions…

Expert Care in Little Rock

Access metastatic prostate cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic prostate cancer treatment provided free

Apply for This Little Rock Location

Check if you qualify for this metastatic prostate cancer clinical trial in Little Rock, AR

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Little Rock

    Convenient for AR residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Little Rock site if eligible
  4. 4Begin participation

About This Metastatic Prostate Cancer Study in Little Rock

The study is being done to see if a small daily dose of naltrexone (LDN, 3 mg pill) can help reduce tiredness (fatigue) in men with prostate cancer. All men in this study are being treated with hormone therapy (also called androgen deprivation therapy, or ADT). Some may also be taking newer hormone medicines such as apalutamide, daralutamide, enzalutamide, or abiraterone.

Sponsor: University of Arkansas

Who Can Participate

Inclusion Criteria

Histologically or cytologically confirmed biochemical recurrence and on ADT for at least 3 months. Metastatic castrate-sensitive and castrate-resistant prostate cancer on ADT with or without novel hormonal therapy like apalutamide, darolutamide, enzalutamide and abiraterone.
Initiation of hormonal ablative therapy within 3 months of registration.
ECOG performance status \<3.
Patients must have normal organ and marrow function as defined below:
leukocytes \>3,000/μL
absolute neutrophil count \>1,500/μL
platelets \>100,000/μL
total bilirubin within normal institutional limits
AST(SGOT)/ALT(SGPT) \<2.5 X institutional upper limit of normal
creatinine ≤2.5.0
left ventricular ejection fraction \>45%
FACIT-F score \< 43 on screening
Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

Prior chemotherapy received in the last three months.
Patients currently on PARP inhibitors.
Currently taking or have taken within 10 days of enrollment.
Patients may not be receiving any other investigational agents.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Naltrexone or other agents used in the study.
History of other malignancies other than nonmelanoma skin cancer, unless in complete remission and off therapy for that disease for at least 5 years.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, history of congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Any Patient with acute hepatitis and liver failure are excluded.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Little Rock?

Yes, this clinical trial (NCT07224009) has an active research site in Little Rock, AR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Prostate Cancer Treatment Options in Little Rock, AR

If you're searching for metastatic prostate cancer treatment options in Little Rock, AR, this clinical trial (NCT07224009) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Little Rock research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced metastatic prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic prostate cancer clinical trials near you to find additional studies recruiting in your area.

More Prostate Cancer Trials in Little Rock, AR

See all prostate cancer clinical trials recruiting in Little Rock — not just this study.

Browse Prostate Cancer Trials in Little Rock →

Browse More Trials by Condition

Prostate Cancer TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Little Rock?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Little Rock, AR